Misplaced Pages

Laninamivir

Clinical data
Routes of administration	Inhalation
ATC code	J05AH04 (WHO)
Identifiers
IUPAC name (4S,5R,6R)-5-acetamido-4-carbamimidamido-6--5,6-dihydro-4H-pyran-2-carboxylic acid
CAS Number	203120-17-6
PubChem CID	502272
ChemSpider	439182
UNII	B408IW3GL5
ChEMBL	ChEMBL466246
CompTox Dashboard (EPA)	DTXSID60942457
Chemical and physical data
Formula	C13H22N4O7
Molar mass	346.340 g·mol
3D model (JSmol)	Interactive image
SMILES O=C(O)C=1O((OC)(O)CO)(NC(=O)C)(/N=C(\N)N)C=1
InChI InChI=1S/C13H22N4O7/c1-5(19)16-9-6(17-13(14)15)3-8(12(21)22)24-11(9)10(23-2)7(20)4-18/h3,6-7,9-11,18,20H,4H2,1-2H3,(H,16,19)(H,21,22)(H4,14,15,17)/t6-,7+,9+,10+,11+/m0/s1 Key:QNRRHYPPQFELSF-CNYIRLTGSA-N
(what is this?)  (verify)

Laninamivir (CS-8958) is a neuraminidase inhibitor that is a drug used for the treatment and prophylaxis of Influenzavirus A and Influenzavirus B. It is currently in Phase III clinical trials. It is a long-acting neuraminidase inhibitor administered by nasal inhalation.

Laninamivir was approved for influenza treatment in Japan in 2010 and for prophylaxis in 2013. It is currently marketed under the name Inavir by Daiichi Sankyo. Biota Pharmaceuticals and Daiichi Sankyo co-own Laninamivir. On 1 April 2011, BARDA awarded up to an estimated U$231m to Biota Pharmaceuticals (Formerly Biota Holdings Ltd) wholly owned subsidiary, Biota Scientific Management Pty Ltd, for the advanced development of Laninamivir in the US. It is under clinical evaluations in other countries.

References

1. Yamashita M, Tomozawa T, Kakuta M, Tokumitsu A, Nasu H, Kubo S (January 2009). "CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity". Antimicrobial Agents and Chemotherapy. 53 (1): 186–192. doi:10.1128/AAC.00333-08. PMC 2612152. PMID 18955520.
2. Hayden F (January 2009). "Developing new antiviral agents for influenza treatment: what does the future hold?". Clinical Infectious Diseases. 48. 48 Suppl 1 (S1): S3-13. doi:10.1086/591851. PMID 19067613.
3. ^ Samson M, Pizzorno A, Abed Y, Boivin G (May 2013). "Influenza virus resistance to neuraminidase inhibitors". Antiviral Research. 98 (2): 174–185. doi:10.1016/j.antiviral.2013.03.014. PMID 23523943.
4. "Aviragen Therapeutics - Home". Archived from the original on 2016-04-17. Retrieved 2013-04-12.
5. "Biota Pharmaceuticals - Home". Archived from the original on 2016-03-05. Retrieved 2013-04-12.
6. Ishjida T (2020). "Treatment Guidelines for Influenza Virus Infection: What Does the Recent Guideline State?". In Fujita J (ed.). Influenza: Advances in Diagnosis and Management. Respiratory Disease Series: Diagnostic Tools and Disease Managements. Singapore: Springer. pp. 129–136 (132). doi:10.1007/978-981-15-9109-9_13. ISBN 978-981-15-9109-9. S2CID 228892521.

This antiinfective drug article is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

• Guanidines
• Neuraminidase inhibitors
• Dihydropyrans
• Acetamides
• Antiinfective agent stubs